Comparation between Fibroscan and Hepatus for Detecting NAFLD in Patients with Metabolic Dysregulation

Jie-hui Sun(1), Ping-ping Zhang(2), Kun Wang(3), Miao Xu(4), Jing Sun(5), Li Li(6),

(1) Department of Endocrinology and Metabolism, The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang Province,
(2) Ningbo Center for Healthy Lifestyle Research, The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang Province
(3) Department of Endocrinology and Metabolism, The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang Province
(4) Department of Endocrinology and Metabolism, The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang Province
(5) School of Medicine and Dentistry, Griffith University, Queensland
(6) Department of Endocrinology and Metabolism, The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang Province
Corresponding Author


Background The clinical application of the innovative instantaneous elasticity and fat attenuation measurement technology, Hepatus, is currently in the evaluation stage. This study aimed to compare the detection performance of Fibroscan and Hepatus in patients with metabolic dysregulation who are "at-risk" for non-alcoholic fatty liver disease (NAFLD).

Methods Between January 2021 and April 2021, 149 patients were enrolled in this study. Clinical data were collected, and all patients underwent both Fibroscan and Hepatus assessments to determine liver stiffness measurement (LSM) and attenuation parameters. The correlation between the results obtained from the two transient elastography (TE) devices was analyzed. Receiver operating characteristic curves (ROC) were constructed to compare the diagnostic value of Fibroscan and Hepatus for Hepatic Steatosis Index (HSI)-based NAFLD.

Results The detection success rate of Hepatus (100.0%) was higher than that of Fibroscan (96.0%). LSM (r = 0.663, P<0.05) and attenuation parameters (r = 0.778, P<0.05) obtained by Fibroscan and Hepatus were significantly correlated. Hepatus tended to produce a higher LSM (Hepatus vs. Fibroscan: 6.04 vs. 5.66 kPa, P=0.016) but a lower attenuation parameter than Fibroscan (Hepatus vs. Fibroscan: 264 vs. 277 dB/m, P<0.001). The area under the ROC curve for detecting HSI-based NAFLD was 0.811 for Fibroscan and 0.832 for Hepatus.

Conclusion Measurements obtained by Fibroscan and Hepatus are strongly correlated, and the diagnostic value of the two TE devices is comparable in detecting HSI-based NAFLD. Hepatus offer a potential TE alternative in NAFLD examination.



Younossi, Z.M., et al., The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology, 2023. 77(4): p. 1335-1347.

Tapper, E.B. and N.D. Parikh, Mortality due to cirrhosis and liver cancer in the United States, 1999-2016: observational study. Bmj, 2018. 362: p. k2817.

Kim, D., et al., Changing Trends in Etiology-Based Annual Mortality From Chronic Liver Disease, From 2007 Through 2016. Gastroenterology, 2018. 155(4): p. 1154-1163.e3.

Rinella, M.E., et al., AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology, 2023. 77(5): p. 1797-1835.

Barr, R.G., et al., Update to the Society of Radiologists in Ultrasound Liver Elastography Consensus Statement. Radiology, 2020. 296(2): p. 263-274.

EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol, 2015. 63(1): p. 237-64.

Dietrich, C.F., et al., EFSUMB Guidelines and Recommendations on the Clinical Use of Liver Ultrasound Elastography, Update 2017 (Long Version). Ultraschall Med, 2017. 38(4): p. e48.

Ferraioli, G., et al., WFUMB guidelines and recommendations for clinical use of ultrasound elastography: Part 3: liver. Ultrasound Med Biol, 2015. 41(5): p. 1161-79.

Mueller, S. and L. Sandrin, Liver stiffness: a novel parameter for the diagnosis of liver disease. Hepat Med, 2010. 2: p. 49-67.

Sasso, M., et al., Controlled attenuation parameter (CAP): a novel VCTE™ guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol, 2010. 36(11): p. 1825-35.

Karlas, T., et al., Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J Hepatol, 2017. 66(5): p. 1022-1030.

Mózes, F.E., et al., Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. Gut, 2021.

Boursier, J., et al., Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease. J Hepatol, 2016. 65(3): p. 570-8.

Nguyen-Khac, E., et al., Non-invasive diagnosis of liver fibrosis in patients with alcohol-related liver disease by transient elastography: an individual patient data meta-analysis. Lancet Gastroenterol Hepatol, 2018. 3(9): p. 614-625.

Eddowes, P.J., et al., Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology, 2019. 156(6): p. 1717-1730.

Ren, X., et al., A New Visual Transient Elastography Technique for Grading Liver Fibrosis in Patients With Chronic Hepatitis B. Ultrasound Q, 2020. 37(2): p. 105-110.

Ren, X., et al., Analysis of liver steatosis analysis and controlled attenuation parameter for grading liver steatosis in patients with chronic hepatitis B. Quant Imaging Med Surg, 2021. 11(2): p. 571-578.

Eslam, M., et al., A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol, 2020. 73(1): p. 202-209.

Zhou, B.F., Predictive values of body mass index and waist circumference for risk factors of certain related diseases in Chinese adults--study on optimal cut-off points of body mass index and waist circumference in Chinese adults. Biomed Environ Sci, 2002. 15(1): p. 83-96.

Alberti, K.G., P. Zimmet, and J. Shaw, The metabolic syndrome--a new worldwide definition. Lancet, 2005. 366(9491): p. 1059-62.

Zhang, Y., W. Wang, and G. Ning, Metabolic Management Center: An innovation project for the management of metabolic diseases and complications in China. J Diabetes, 2019. 11(1): p. 11-13.

Lee, J.H., et al., Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Dis, 2010. 42(7): p. 503-8.

Shih, K.L., et al., Comparisons of parallel potential biomarkers of 1H-MRS-measured hepatic lipid content in patients with non-alcoholic fatty liver disease. Sci Rep, 2016. 6: p. 24031.

Boursier, J., et al., Determination of reliability criteria for liver stiffness evaluation by transient elastography. Hepatology, 2013. 57(3): p. 1182-91.

Abeysekera, K.W.M., et al., Prevalence of steatosis and fibrosis in young adults in the UK: a population-based study. Lancet Gastroenterol Hepatol, 2020. 5(3): p. 295-305.

Younossi, Z., et al., Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol, 2018. 15(1): p. 11-20.

Lee, S.S. and S.H. Park, Radiologic evaluation of nonalcoholic fatty liver disease. World J Gastroenterol, 2014. 20(23): p. 7392-402.

Castera, L., M. Friedrich-Rust, and R. Loomba, Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology, 2019. 156(5): p. 1264-1281.e4.

Wong, V.W., et al., Noninvasive biomarkers in NAFLD and NASH - current progress and future promise. Nat Rev Gastroenterol Hepatol, 2018. 15(8): p. 461-478.

Goyal, R., et al., Fibroscan can avoid liver biopsy in Indian patients with chronic hepatitis B. J Gastroenterol Hepatol, 2013. 28(11): p. 1738-45.

Jessica Cynthia Febryani, et al., Comparison between Hepatus® and Fibroscan® for Evaluating Liver Fibrosis in Chronic Hepatitis B. The Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy, 2020. 23(2): p. 112-116.

Zhang, X., G.L. Wong, and V.W. Wong, Application of transient elastography in nonalcoholic fatty liver disease. Clin Mol Hepatol, 2020. 26(2): p. 128-141.

Anstee, Q.M., L. Castera, and R. Loomba, Impact of non-invasive biomarkers on hepatology practice: Past, present and future. J Hepatol, 2022. 76(6): p. 1362-1378.

Wan, T., et al., Applicability and Results of Liver Stiffness Measurement and Controlled Attenuation Parameter Using XL Probe for Metabolic-Associated Fatty Liver Disease in Candidates to Bariatric Surgery. A Single-Center Observational Study. Obes Surg, 2021. 31(2): p. 702-711.

Full Text: PDF

Article Metrics

Abstract View : 75 times
PDF Download : 37 times

DOI: 10.24871/251202411-20


  • There are currently no refbacks.